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Abstract
Brain-derived neurotrophic factor (BDNF), a neuromodulator involved in nociceptive hypersensitivity in the central nervous
system, is also expressed in synoviocytes of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. We investigated the
role of P2 purinoreceptors in the induction of BDNF expression in synovial fibroblasts (SF) of OA and RA patients. Cultured
SF from patients with symptomatic knee OA and RA were stimulated with purinoreceptor agonists ATP, ADP, or UTP. The
expression of BDNF mRNA was measured by quantitative TaqMan PCR. BDNF release into cell culture supernatants was
monitored by ELISA. P2X4 expression in synovial tissue was detected by immunohistochemistry. Endogenous P2X4
expression was decreased by siRNA transfection before ATP stimulation. Kinase pathways were blocked before ATP
stimulation. BDNF mRNA expression levels in OASF were increased 2 h and 5 h after ATP stimulation. Mean BDNF levels in
cell culture supernatants of unstimulated OASF and RASF were 19 (69) and 67 (649) pg/ml, respectively. BDNF levels in SF
supernatants were only elevated 5 h after ATP stimulation. BDNF mRNA expression in OASF was induced both by P2X
receptor agonists ATP and ADP, but not by UTP, an agonist of P2Y purinergic receptors. The ATP-induced BDNF mRNA
expression in OASF was decreased by siRNA-mediated reduction of endogenous P2X4 levels compared to scrambled
controls. Inhibition of p38, but not p44/42 signalling reduced the ATP-mediated BDNF mRNA induction. Here we show a
functional role of the purinergic receptor P2X4 and p38 kinase in the ATP-induced expression and release of the
neurotrophin BDNF in SF.
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Introduction
Osteoarthritis (OA) and rheumatoid arthritis (RA), the most
frequent joint diseases, are typically accompanied by chronic pain.
Several studies demonstrated that the concordance between joint
pain and radiological abnormality is poor [1]. There is mounting
evidence indicating that compounds which act as mediators of
pain in the nervous system also play a functional role in the
synovial tissue. Synovial fibroblasts (SF) were shown to release an
array of cytokines and growth factors that act on diverse cells
including neurons. Therefore, SF have the capacity to modulate
inflammation and promote matrix degradation and to play a
central role in the development of joint pain [2]. In many studies,
OASF are compared with RASF, due to the lack of normal SF
from healthy individuals [3].
Brain-derived neurotrophic factor (BDNF) is known as a crucial
neuromodulator involved in nociceptive hypersensitivity in the
central nervous system [4] and BDNF levels are modified in some
persistent pain states as well as in inflammation [5,6,7,8]. BDNF
exerts its action via binding to the high affinity receptor
tropomyosine receptor kinase B (TrkB) or the low affinity receptor
p75
NTR, which is capable of binding all neurotrophins [9]. The
function of BDNF in the central nervous system has been studied
in detail [10]. Recently, a role of neurotrophins as important
factors in arthritis has been discussed [11]. High BDNF mRNA
expression levels as well as expression of the receptors TrkB and
p75
NTR were detected in synovial fluid cells of OA, RA and
spondyloarthritis patients [12]. Moreover, a positive immuno-
staining for BDNF, TrkB and p75
NTR in synovial tissue sections of
OA and RA patients was reported [13]. TrkB staining was
detected in nerve fibres in synovial tissue sections of knee OA and
RA patients [13,14]. In addition, TrkB expression was shown in
articular chondrocytes and inflammatory infiltrates in knee joints
of local injection-induced mice [15]. An increased BDNF
immunostaining in SF and macrophages in synovial tissue of
OA and RA patients compared to healthy controls has been
reported previously [16], but the regulation of BDNF expression in
SF is still unknown.
Extracellular ATP levels are increased in inflamed or damaged
tissues and the nucleotide is found in the synovial fluid of arthritis
patients[17].ATPsignallingismediatedbyP2purinoreceptorsthat
are divided into two families, ionotropic receptors P2X and
metabotropic receptors P2Y. P2X receptors (P2X1–P2X7) contain
intrinsicporesthatopenbybindingATP,andP2Yreceptors(P2Y1,
2, 4, 6, 11, 12, 13, 14) are activated by nucleotides and couple to
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proteins. Recently, the P2X4 receptor-mediated release of BDNF
from rat microglia was shown to be dependent on calcium and p38
mitogen-activated protein kinase (MAPK) [18]. We aimed to
investigatewhetherSFarecapableofsecretingBDNFandtoidentify
the underlying mechanism. Here, we report a functional role of the
purinergicreceptorP2X4intheATP-inducedexpressionandrelease
of the neurotrophinBDNF in SF.
Results
ATP Induces the Expression of BDNF in SF of Arthritic
Patients
Time course experiments revealed an increased BDNF mRNA
expression in OASF 2 h (15.266.0 fold, n=11, p,0.001) and 5 h
(4.263.1 fold, n.s.) after ATP stimulation compared to unstimu-
lated cells (Fig. 1A). After 24 h ATP stimulation, BDNF mRNA
levels returned to control levels. In RASF, BDNF mRNA levels
were also elevated 2 h (10.866.9 fold, n=6, p,0.001) and 5 h
(2.661.4 fold, n.s.) after ATP stimulation (Fig. 1A). This effect was
not dose-dependent at high mM ATP concentrations (Fig. 1B),
since the reduction of ATP to a concentration of 50 mMo ra
further increase to 200 mM and 500 mM ATP did not affect BDNF
mRNA levels in 2 h stimulated OASF (n=8) and RASF (n=5).
Whereas 1 mM ATP only mildly stimulated BDNF mRNA
expression, a concentration of 20 mM ATP was sufficient to
completely activate BDNF mRNA expression in OASF (n=6). In
order to validate the effect of elevated ATP concentrations on
BDNF protein levels, BDNF was measured in cell culture
supernatants of stimulated and unstimulated OASF (n=11) and
RASF (n=6). Mean BDNF levels in cell culture supernatants of
unstimulated OASF (n=8) and RASF (n=6) were 19 (69) and 67
(649) pg/ml (p,0.05), respectively (Fig. 1C). Outliers from three
OA patients were excluded from this analysis since these patients
showed 14-fold increased BDNF levels (266636 pg/ml) compared
to all other OASF. Interestingly, these three patients were the only
ones that have received centrally acting drugs. BDNF levels in
OASF supernatants (Fig. 1D) were increased (1226136 pg/ml,
p,0.05) 5 h after ATP stimulation. Similar results were obtained
for RASF (2226148 pg/ml, p,0.05) after 5 h ATP stimulation.
ATP and ADP, but not UTP Induce BDNF Expression
Expression of several P2 purinoreceptors in OA and RA
synoviocytes was, at least on the mRNA level, reported previously
[19,20]. In order to narrow the number of possibly involved
receptors down that mediate the induction of BDNF, OASF
(n=8) and RASF (n=3) were stimulated with purinoreceptor
agonists ATP, ADP or UTP for 2 h. BDNF mRNA levels were
induced by P2X receptor agonists ATP (OASF: 11.064.3 fold,
p,0.001; RASF: 13.466.3 fold, p,0.05) and ADP (OASF:
10.562.9 fold, p,0.001; RASF: 12.965.8 fold, p,0.05), but not
UTP (OASF: 1.260.5 fold, n.s.; RASF: 0.860.3 fold, n.s.), a P2Y
receptor agonist (Fig. 2). These results highly suggested a role for
the purinoreceptor P2X4 in the ATP-induced regulation of BDNF
expression. The probability for the involvement of other P2X
receptors was low, since they preferentially respond to either much
lower ATP concentrations (P2X1,3) or high ATP concentrations
(P2X7), respectively [21].
The P2X4 Receptor is Expressed in SF
Since the expression of P2X4 in SF was so far only verified on
mRNA levels [20], we investigated the expression of this receptor
(brown) by immunohistochemistry (Fig. 3) and double stained with
a fibroblast marker (green). Our double staining of OA and RA
synovial tissue (n=4) revealed that the P2X4 receptor is present in
SF but also in other non-fibroblast cell types.
The Receptor P2X4 is Involved in the ATP-induced
Expression of BDNF
In order to investigate the potential role of P2X4 in the ATP-
mediated induction of BDNF, we reduced endogenous P2X4
levels in OASF (n=8) using siRNA transfections and repeated the
ATP stimulation experiments. The ATP-induced BDNF mRNA
expression was decreased (control: 6.463.5 fold, siP2X4: 3.561.9
fold, p,0.05) by siRNA-mediated reduction of endogenous P2X4
levels in OASF compared to scrambled controls (Fig. 4A). The
reduction of P2X4 mRNA and protein expression levels were
verified by Real-time PCR (Fig. 4A) as well as Western blotting
(Fig. 4B) followed by densitometric analysis of band intensities.
Endogenous P2X4 levels were reduced by transfection of P2X4
specific siRNA (37.8619%, p,0.001) compared to scrambled
controls (Fig. 4C).
The ATP-induced BDNF Expression is Dependent on p38
MAPK Signalling
Since the P2X4 receptor-mediated release of BDNF from rat
microglia was shown to be dependent on p38 MAPK signalling
[18] we asked, whether this pathway is also active in SF.
Therefore, we monitored the phosphorylation of p38 and p44/
42 kinases in cell extracts of ATP stimulated OASF in a time
course experiment. Both, p38 MAPK and p44/42 MAPK were
already phosphorylated within 10 minutes of ATP stimulation
(Fig. 5A). The kinase activation was temporally limited since the
effect was gone 2 h after starting the ATP treatment. In order to
investigate whether these kinases are involved in the ATP-induced
expression of BDNF, we treated OASF (n=10) and RASF (n=3)
with the p38 MAPK inhibitor SB203580, the p44/42 inhibitor
FR180204 and the MEK inhibitor PD98059 15 minutes prior
ATP stimulation. The ATP-induced mRNA expression of BDNF
was significantly reduced in SB203580 pretreated OASF (8.662.8
fold, n=10, p,0.05) compared to controls (12.864.6 fold).
Pretreatment with other kinase inhibitors had no effect (Fig. 5B).
Similar results were obtained in RASF although results did not
reach statistical significance due to low patient numbers.
Transfection of p38 Kinase siRNA Reduced ATP-induced
BDNF Expression
To further analyse the involvement p38 and p44/42 MAPK in
the hypothesized pathway, we transfected OASF (n=6) with
siRNAs targeting all isoforms of p38 and p44/42 MAPK prior
ATP stimulation. The expression levels of p38 (62.0621.7%,
p,0.05) and p44/42 MAPK (39.7613.1%, p,0.05) were
significantly reduced after siRNA transfection compared to
controls (Fig. 6A, B). The blockade of p38 (3.261.5 fold,
p,0.05) but not p44/42 (4.661.8 fold, n.s.) MAPK signalling
reduced the ATP-induced increase in BDNF mRNA expression
compared to scrambled controls (5.762.2 fold; Fig. 6C).
Discussion
For the first time, we provide evidence for the functional
expression of the purinergic receptor P2X4 in SF of patients with
symptomatic knee OA and RA. Interestingly, P2X4 activation in
SF mediates an increase in BDNF expression and release from SF.
By using pharmacological, as well as siRNA-mediated inhibition of
kinase pathways in SF, we were able to show that the ATP-
mediated induction of BDNF is dependent on p38 MAPK
BDNF in Osteoarthritis Joint Pain
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aminoterminal kinase (data not shown). Therefore, the underlying
basic mechanism in non-glial SF is similar to the signalling cascade
recently described for microglia [18]. However, we also observed
some differences between BDNF induction in SF and microglia:
Trang et al. reported a biphasic release of BDNF at 5 and 60
minutes after ATP stimulation [18], reflecting an immediate
release of vesicle-stored BDNF and a delayed secretion of de novo
synthesized BDNF. We were not able to detect an immediate
release of pre-synthesized BDNF within minutes after stimulation
as it was shown for microglia. An increased BDNF mRNA
synthesis in SF was detectable 2 h after ATP stimulation and the
BDNF release was time-delayed with a peak at 5 h. The ATP-
induced BDNF expression in rat astrocytes was reported to be
mediated by activation of the purinergic receptor P2Y1, Ca
2+/
calmodulin dependent kinase signalling and the phosphorylation
of the transcription factor cAMP-responsive element-binding
protein (CREB) [22]. Although we observed a phosphorylation
of CREB in OASF after 10 minutes ATP stimulation, siRNA
experiments reducing endogenous CREB expression levels
revealed that CREB is not involved in the ATP-induced
transcription of BDNF in SF (see Fig. S1).
Purinergic receptors are expressed in glial cells and P2X/P2Y
receptor-mediated signalling critically contributes to the develop-
ment and maintenance of neuropathic pain [23]. P2X receptor-
mediated excitation of nociceptive afferents in normal and
arthritic rat knee joints was shown previously [17]. Expression of
Figure 1. ATP-induced BDNF expression in SF. OASF (n=11) and RASF (n=6) were stimulated with ATP (50, 100, 200, 500 mM) for 10 minutes,
2 h, 5 h and 24 h. A. BDNF mRNA levels were induced 2 h after ATP stimulation. B. Influence of different ATP concentrations on the induction levels
of BDNF mRNA after 2 h ATP stimulation. C. BDNF protein levels in cell culture supernatants of unstimulated OASF (n=8) and RASF (n=6) were
measured by ELISA. D. BDNF protein levels in cell culture supernatants of OASF and RASF were elevated 5 h after ATP stimulation. Data are shown as
means 6 standard deviations. N.s., not significant; *, p,0.05, ***, p,0.001.
doi:10.1371/journal.pone.0036693.g001
Figure 2. Purinergic receptor P2X, but not P2Y agonists induce
BDNF expression. OASF (n=8) and RASF (n=3) were stimulated for
2 h with 100 mM ATP, ADP and UTP, respectively. BDNF mRNA
expression was increased by ATP and ADP, but not by UTP. Data are
shown as means 6 standard deviations. N.s., not significant; *, p,0.05,
***, p,0.001.
doi:10.1371/journal.pone.0036693.g002
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least on the mRNA level, reported previously and a functional role
for P2X1, P2X3 and P2X7 in modulation of inflammatory
responses was suggested [19,20]. A couple of purinergic receptors
were linked to the development of pain in animal models. The
activation of P2X4 in microglia was reported to play a role in
tactile allodynia in rats [24]. Moreover, ATP-stimulated BDNF in
rat microglia was shown to act as an important signalling molecule
between microglia and neurons in pain transmission [25].
Furthermore, disruption of the P2X7 gene in mice abolished
chronic inflammatory pain and neuropathic pain [26]. A role for
P2Y12 receptors in neuropathic pain development in microglia
has been described by two studies in mice [27,28]. Various P2X
purinergic receptor ligands have been patented by diverse
pharmaceutical companies in the last years since these compounds
may be useful drugs for the treatment of arthritis, pain,
inflammation and neurodegenerative diseases [29]. So far, no
functional role for purinergic receptors has been described in pain
development in human joints. Though, a correlation of synovial
fluid ATP levels and OA-associated knee pain in patients has been
reported recently [30]. Our double staining of OA synovial tissues
revealed that the P2X4 receptor is present in SF but also in other
non-fibroblast cell types, most likely endothelial cells and
macrophages. The expression of P2X4 in endothelial cells in
vessels [31], as well as in macrophages is well established.
Recently, the P2X4 mediated release of prostaglandin E2
(PGE2) by macrophages was shown to initiate inflammatory pain
in mice [32]. Since prostaglandins were also shown to be capable
of inducing BDNF secretion from human glial cell lines [33], we
excluded an indirect effect of prostaglandins on ATP-induced
BDNF expression using a cyclooxygenase inhibitor (see Fig. S2).
Increased BDNF expression levels in the peripheral nerve,
dorsal root ganglion (DRG) and dorsal horn have been described
in different animal models of neuropathic pain [4]. A local
injection of BDNF into the rat hind paw was shown to cause
thermal hyperalgesia [34], and exogenous BDNF directly deliv-
ered to the intact DRG caused mechanical allodynia [35]. An
increased BDNF expression was reported in DRG neurons in the
selective spinal nerve ligation animal model [36]. Furthermore,
BDNF has been described in inflammatory pain states. In humans,
BDNF expression in the pancreas is upregulated and associated
with pain in chronic pancreatitis [7]. In rats, BDNF expression
levels in bladder were increased in models of bladder inflammation
[6]. Moreover, colonic BDNF expression levels were increased in
mouse models of inflammatory bowel disease, suggesting a role for
BDNF in colonic hypersensitivity [5,8]. The expression of BDNF
in human SF was reported earlier [13,16] and BDNF was shown
to be particularly expressed under more inflammatory conditions
in synovial tissue [16]. Our results also showed an increased
BDNF secretion from RASF compared to OASF in unstimulated
conditions. Barthel et al. also reported a slightly elevated BDNF
mRNA expression in synovial fluid cells of RA compared to OA
Figure 3. Immunohistochemistry. Representative photomicrographs showing immunohistochemical double staining of OA and RA synovial
tissues with P2X4 (brown) and fibroblast marker (green). A. original magnification 4006, box shows the Isotype control, magnification 2006.
B. original magnification 6306.
doi:10.1371/journal.pone.0036693.g003
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indicate that basal BDNF levels highly vary amongst patients and
it seems that central acting medication strongly increases BDNF
expression levels. The OA patients exhibiting 14-fold increased
basal BDNF levels were medicated with amitriptyline, the opioid
analgesic oxycodon and the benzodiazepine oxazepam. Increased
serum BDNF concentrations were reported in depressed patients
treated with amitriptyline [37] and this drug was shown to induce
the production of BDNF in whole blood cell cultures derived from
healthy individuals [38]. To our knowledge, no literature linking
oxycodon and oxazepam, respectively with BDNF is available.
However, other benzodiazepines [39,40] as well as other opioides
[41,42,43] were shown to increase BDNF expression levels.
The fact that SF are capable of secreting BDNF actively upon
increased ATP levels, a signal of inflamed and damaged tissue, is
entirely new. So far, there are few data available about other signals
than ATP regulating BDNF secretion in diverse cell types. An
increased BDNF secretion has been observed upon stimulation of
monocytes, B- and T- cells [44]. Cytokines, such as tumor necrosis
factor- a (TNF- a) and interleukin-6 (IL-6) were shown to induce
BDNFsecretionfrommonocytes[45].Stimulationofmicrogliacells
with IL-17 resulted in increased BDNF, nerve growth factor (NGF)
and glia-derived neurotrophic factor (GDNF) expression levels and
release[46].Raychaudhurietal.showedthatstimulationofSFwith
IL1-bandTNF-aresultedinanincreasedNGFrelease,butBDNF
expression and release were not studied [47].
In conclusion, we showed that the ATP-induced expression and
release of the neurotrophin BDNF is dependent on P2X4 and on
p38 MAPK signalling. It is interesting that the pathway operating
in microglia is also observed in non-glial SF. A potential functional
role for BDNF in pain transmission in synovial tissues in vivo
remains to be investigated.
Materials and Methods
Tissue Samples and Cell Culture
SF were obtained from symptomatic knee OA and RA patients
that underwent joint replacement surgery in the Schulthess Clinic
Zurich. Informed consent was obtained from all patients. All
patients fulfilled the criteria for the classification of OA [48] and
RA [49], respectively. Cells were cultured as described elsewhere
[50] and used between passages 4 to 9 for all experiments.
Stimulation of Cells
For stimulation experiments 2610
5 cells were cultured in 6-well
plates. 24 h prior stimulation, cells were serum starved in
DMEM/F-12 (Invitrogen, Basel, Switzerland) supplemented with
0.5% fetal calf serum (FCS; Invitrogen). SF were stimulated with
ATP (50, 100, 200, 500 mM; Sigma-Aldrich, Buchs, Switzerland)
for 10 min, 2 h, 5 h and 24 h, as well as ADP (100 mM; Sigma-
Aldrich) and UTP (100 mM; Sigma-Aldrich) for 2 h. In kinase
inhibitor experiments, cells were treated with 5 mg/ml of the p38
MAPK inhibitor SB203580 (Calbiochem, Darmstadt, Germany),
30 mM of the ERK inhibitor II FR180204 (Calbiochem) and
50 mM of the MAPK kinase (MEK) inhibitor PD98059 (Calbio-
chem) 15 minutes prior ATP stimulation for 2 h. Cells were
Figure 4. Purinergic receptor P2X4 siRNA transfection in OASF (n=8). Endogenous P2X4 expression in OASF was reduced by siRNA
transfection before ATP (100 mM) stimulation for 2 h. A. P2X4 mRNA expression was reduced compared to scrambled controls. The ATP-induced
BDNF mRNA expression in P2X4 siRNA transfected cells was reduced compared to scrambled controls. B. P2X4 protein levels were reduced by P2X4
siRNA transfection compared to scrambled controls. a-tubulin levels in P2X4 siRNA transfected cells were slightly decreased compared to controls
due to experimental conditions. C. Densitometric analysis of Western blot results. Data are shown as means 6 standard deviations. N.s., not
significant; *, p,0.05, ***, p,0.001.
doi:10.1371/journal.pone.0036693.g004
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Western blot analysis, respectively. Cell culture supernatants were
collected and stored at 280uC for enzyme-linked immunosorbent
assay (ELISA) experiments.
Isolation of RNA, Reverse Transcription, and Quantitative
Real-Time PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Hombrechtikon, Switzerland) including on-column DNaseI (Qia-
gen) digest and reversed transcribed using MultiScribe reverse
transcriptase and random hexamer primers (Applied Biosystems,
Rotkreuz, Switzerland). Real-time PCR was performed on the
ABI PRISM 7700 Sequence Detector System (Applied Biosystems)
by using the TaqMan Gene Expression Assays Hs00380947_m1
and Hs00602442_m1 for human BDNF and P2X4 (Applied
Biosystems), respectively. Constitutively expressed human glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) was measured for
internal standard sample normalization using SYBR Green
(Applied Biosystems) and primers as described elsewhere [51].
Relative mRNA expression levels were calculated by the
comparative threshold cycle method (DDCt).
BDNF ELISA
Cell culture supernatants from unstimulated as well as from
ATP stimulated cells were concentrated using Amicon Ultra
0.5 ml Centrifugal Filters (Milian AG, Geneva, Switzerland) with
a molecular weight cut off of 10 kDa. BDNF release into cell
culture supernatants was measured using the RayBio Human
BDNF ELISA kit (Lucerna-Chem AG, Luzern, Switzerland)
according to the manufacturer’s instructions.
Western Blot Analysis
Cells from 6-well plates were lysed directly in 200 ml Lemmli
buffer (62.5 mM TrisHCl, 2% SDS, 10% Glycerol, 0.1%
Bromphenolblue, 5 mM b-mercaptoethanol). Whole cell lysates
were separated on 10% SDS polyacrylamide gels and electro-
blotted onto nitrocellulose membranes (Whatman, Dassel,
Germany). Membranes were blocked for 1 h in 5% (w/v) non-
fat milk in TBS-T (20 mM Tris base, 137 mM sodium chloride,
0.1% Tween 20, pH 7.6). After blocking, the membranes were
probed with antibodies against P2X4 receptor (Alomone Labs,
Jerusalem, Israel; 1:200), p38 MAPK (Cell Signaling, Allschwil,
Switzerland; 1:1000), phospho-p38 (p-p38) MAPK (Cell Signal-
ing; 1:1000), p44/42 MAPK (Cell Signaling; 1:1000), phospho-
p44/42 (p-p44/42) MAPK (Cell Signaling; 1:1000), and a-
tubulin (Abcam, Cambridge, UK; 1:5000), respectively. After
three washes with TBS-T, the horseradish peroxidase-conjugated
secondary goat anti-rabbit antibody or goat anti-mouse antibody
(Jackson ImmunoResearch, Suffolk, UK) was added at a dilution
of 1:5000 in 5% (w/v) non-fat milk/TBS-T for 1 h. Blots were
washed three times in TBS-T, followed by detection with the
ECL Western blotting detection reagents (GE Healthcare,
Glattbrugg, Switzerland) and exposured on Hyperfilm ECL
(GE Healthcare). Evaluation of the expression of specific proteins
was performed by the Alpha Imager Software system (Alpha
Innotech, San Leandro, CA, USA) via pixel quantification of the
electronic image.
Transfection of Cells with siRNA
2610
5 cells were cultured one day before transfection in 6-
well plates. Per transfection (P2X4), 125 ml serum-free Opti-
Figure 5. Activation of MAPK pathways in OASF after ATP stimulation. A. OASF were stimulated with ATP (100 mM) for 10 minutes, 2 h, 5 h
and 24 h. Western blot analysis of p38 and p44/42 MAPK, as well as phosphorylated p-p38 and p-p44/42 MAPK showed kinase activation after 10
minutes ATP stimulation. B. OASF (n=10) and RASF (n=3) were treated with the kinase inhibitors FR180204, SB203580 and PD98059, respectively
15 min before ATP (100 mM) stimulation for 2 h. Data are shown as means 6 standard deviations. *, p,0.05.
doi:10.1371/journal.pone.0036693.g005
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Lipofectamine 2000 reagent (Invitrogen). After 5 minutes,
125 ml serum-free OptiMEM containing either siRNA (Qiagen)
targeting P2X4 (Hs_P2RX4_5) or scrambled siRNA (Ctrl_All-
Stars_1) were added. The transfection solutions were incubated
for 20 minutes at room temperature and then added to 1000 ml
of DMEM/F-12 supplemented with 10% FCS without antibi-
otics contained in each well. The final concentration of siRNA
per well was 40 nM. After 72 h, cells were retransfected for
additional 48 h using the same protocol. 24 h after the second
transfection, cells were serum starved in DMEM/F-12 supple-
mented with 0.5% FCS and treated the day after with 100 mM
ATP for 2 h. For the transfection of siRNAs targeting p38
MAPK, p44/42 MAPK or scrambled SignalSilence Control
siRNA (Cell Signaling, Allschwil, Switzerland) the Amaxa Basic
Nucleofector Kit for Primary Mammalian Fibroblasts (Lonza,
Basel, Switzerland) was used. 2610
5 cells per condition (6
ATP) were resuspended in 100 ml of Nucleofector Solution and
200 nM siRNA were added. The transfection was carried out in
a cuvette using the program U-23 of the Amaxa Nucleofector
device. Afterwards, 500 ml of DMEM/F-12 supplemented with
10% FCS were added immediately. The suspension of one
cuvette was divided into 2 wells on a 6-well plate. 48 h after
transfection, cells were serum starved in DMEM/F-12 supple-
mented with 0.5% FCS and treated the day after with 100 mM
ATP for 2 h. Cells were harvested, and total cellular RNA and
whole-cell lysates were extracted.
Immunohistochemistry
After deparaffinization, sections were pre-treated with citrate
buffer (10 mM sodium citrate, pH 6.0). Endogenous peroxidase
activity was disrupted with 3% H2O2. Nonspecific protein binding
was blocked with 1% bovine serum albumin (BSA)/5% goat
serum for 40 minutes. Polyclonal rabbit anti-P2X4 antibodies
(Alomone Labs) and rabbit IgG1 (isotype control) were applied
(8 mg/ml) over night at 4uC. Slides were washed in PBS-T (0.05%
Tween 20 in PBS) and incubated with biotinylated goat anti-rabbit
antibodies (1:1000; Jackson ImmunoResearch). The signal was
amplified with ABC reagent (Vector Laboratories, Burlingame,
CA) and detected with 3,3 `-diaminobenzidine (DAB; Vector
Laboratories). The next day, slides were blocked as described
above and incubated with monoclonal mouse anti-prolyl-4-
hydroxylase-b (Acris Antibodies, Hiddenhausen, Germany), a
marker enzyme for fibroblasts and as an isotype control, mouse
IgG1 (10 mg/ml). Slides were washed and incubated with
biotinylated goat anti-mouse antibodies (1:2000; Jackson Immu-
noResearch). The signal was amplified using ABC reagent and
detected with HistoGreen (Linaris, Wertheim-Bettingen, Ger-
many) as a substrate.
Statistical Analysis
Statistical analysis on data sets was carried out by using the
GraphPad Prism program (GraphPad Software, San Diego, CA).
Differences between experimental groups were analysed by one-
way analysis of variance (ANOVA) with Tukey’s post hoc test.
Figure 6. Inhibition of p38 and p44/42 MAPK signaling by siRNA transfection. OASF (n=6) were transfected with siRNA targeting p38
MAPK, p44/42 MAPK and scrambled siRNA (control) before ATP (100 mM) stimulation for 2 h. A. Decreased p38 and p44/42 MAPK expression after
siRNA transfection was verified by Western blot analysis. B. Densitometric analysis of Western blot results. C. The ATP-induced BDNF mRNA
expression was reduced in p38 MAPK siRNA transfected OASF but not in p44/42 MAPK siRNA transfected cells. Data are shown as means 6 standard
deviations. *, p,0.05.
doi:10.1371/journal.pone.0036693.g006
BDNF in Osteoarthritis Joint Pain
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36693Differences in basal BDNF levels between OASF and RASF were
analysed by unpaired t test. Wilcoxon signed-rank test was used to
analyse the differences of densitometric intensities of Western blot
results in siRNA experiments. Data are reported as means 6
standard deviations. P values ,0.05 were considered significant.
Supporting Information
Figure S1 cAMP-responsive element-binding protein
(CREB) is not involved in the ATP-induced regulation
of BDNF expression. A. OASF were stimulated with ATP
(100 mM) for 10 minutes, 2 h, 5 h and 24 h. Western blot analysis
of p38 and p44/42 MAPK, phosphorylated p-p38 and p-p44/42
MAPK, as well as phosphorylated p-CREB showed kinase and
CREB activation after 10 minutes ATP stimulation. B. The
reduction of endogenous CREB levels by siRNA transfection in
OASF (n=3) did not affect the C. ATP-mediated increase in
BDNF mRNA expression. Data are shown as means 6 standard
deviations. N.s., not significant; **, p,0.01.
(TIF)
Figure S2 Cyclooxygenase (COX) is not involved in the
ATP-induced regulation of BDNF expression. OASF
(n=6) were stimulated with the COX inhibitor sc-560 (100 nM)
and ATP (100 mM) for 2 h. The ATP-mediated increase in BDNF
expression was not changed by COX-inhibitor treatment. Data
are shown as means 6 standard deviations. N.s., not significant;
*, p,0.05, **, p,0.01.
(TIF)
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